Locations:
SearchSupporting patients during pregnancy and beyond
Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy and after one year after pregnancy. This represents
roughly one in 3,000 pregnancies.
In a recent episode of Cleveland Clinic's Cancer Advances podcast, Erin Roesch, MD, Breast Medical Oncologist discussed:
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Click the podcast player above to listen to the episode now.
Podcast host Dr. Shepard: I'm guessing that managing the complexity of having a breast cancer, coupled with pregnancy, must take a big team. We're going to talk about multidisciplinary care. What does that look like?
Dr. Roesch: Multidisciplinary are includes multiple team members - medical oncologists, breast surgeons, radiation oncologists, genetic counselors, social workers, psychologists, obstetricians, gynecologists and sometimes reproductive providers.
Dr. Shepard: Are there things over time we've learned to do really well?
Where do we need to make improvements?
Dr. Roesch: In terms of some of the psychosocial aspects, we're striving to make improvements and gain a better understanding of the needs of this
population beyond chemotherapy, radiation, and surgery.
It's about having a better understanding of this patient population. Many of these patients may be interested in future pregnancies, so engaging
reproductive endocrinology early on to discuss oncogertility, providing
access to psychologists and social workers, so they're aware that they
have a full team of support. That's an area where continous improvement
could be made.
And in terms of advances in cancer treatment, how do those advances impact
these patients, whether it's in the systemic therapy realm or in surgical
techniques. There's a lot of room to grow.
Advertisement
Advertisement
Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units
Addressing rare disease and challenging treatment course in an active young patient
Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.